馃攳
Search Results - technology+classifications+%3e+therapeutic+modalities+%3e+targets
131
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Method to Inhibit Toxic Pathways Activated in Genetic ALS/FTD
Value PropositionTreatment readily acts via subcutaneous injection and crosses the blood-brain barrier without extra formulation or drug delivery mechanism.Treatment significantly reduces pathological and behavioral phenotypes from toxic proteins coded by genetic defects in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), which...
Published: 3/14/2025
|
Inventor(s):
Shuying Sun
,
Zhe Zhang
Keywords(s):
Category(s):
Clinical and Disease Specializations > Neurology
,
Clinical and Disease Specializations > Neurology > Amyotrophic Lateral Sclerosis
,
Clinical and Disease Specializations > Neurology > Neurodegeneration
,
Clinical and Disease Specializations > Neurology > Motor Neuron Diseases
,
Clinical and Disease Specializations > Neurology > Dementia
,
Technology Classifications > Therapeutic Modalities > Peptides
,
Technology Classifications > Therapeutic Modalities > Targets
,
Technology Classifications > Diagnostics > Biomarkers
Gut-specific serotonin transporter inhibitors for treatment of constipation
Value Proposition路 Potent inhibition of serotonin transporter (SERT) in GI system路 Luminally and or/peripherally-restricted SERT inhibitors路 Result in enhanced action of serotonin in stimulation of GI motility路 Spares the body of systemic and CNS effectsUnmet NeedConstipation-predominant IBS involves reduced gastrointestinal...
Published: 3/13/2025
|
Inventor(s):
Pankaj Pasricha
,
James Barrow
,
Qian Li
,
Pablo de Leon
,
Yifang Huang
Keywords(s):
Antagonists/Inhibitors
,
Biomarker
,
Disease Indication
,
Gastrointestinal Disorders
,
Mechanism-of-action Biomarker
,
Non-novel
,
Predicted Novelty
,
Repurposed
,
Small Molecules
,
Therapeutic Matter
,
Therapeutic Substance
,
Therapeutics
Category(s):
Technology Classifications > Therapeutic Modalities > Targets
,
Clinical and Disease Specializations > Gastroenterology
Activating Mutations in GNAQ Sensitive to Antibiotic; Novel Molecular Pathway and Treatment Target for Capillary Malformations and Related Syndromes
Value Proposition: 路 Antibiotic treatment strategy for capillary malformations and Sturge-Weber Syndrome. 路 Selectively targets endothelial cells with the pathogenic GNAQ mutations using puromycin 路 Inhibits cell proliferation and reduces cell survival via activation of TRP6/NFAT signaling pathway 路 Compatible with various drug...
Published: 3/13/2025
|
Inventor(s):
Anne Comi
,
Jonathan Pevsner
,
Zhenhua Huang
,
Douglas Marchuk
Keywords(s):
Biomarker
,
Disease Indication
,
Genetic Disorders
,
Mechanism-of-action Biomarker
,
Skin Disorders
,
Sturge-Weber Syndrome
,
Sturge-Weber Syndrome (SWS)
,
Target
,
Therapeutic Matter
,
Therapeutics
Category(s):
Clinical and Disease Specializations
,
Clinical and Disease Specializations > Genetic Diseases
,
Clinical and Disease Specializations > Rare Diseases
,
Technology Classifications > Diagnostics > Biomarkers
,
Technology Classifications > Therapeutic Modalities > Targets
,
Clinical and Disease Specializations > Dermatology
,
Technology Classifications > Diagnostics
,
Technology Classifications > Therapeutic Modalities
,
Clinical and Disease Specializations > Dermatology > Sturge-Weber Syndrome
Mitigation of Nuclear Pore defect in Neurodegeneration: ESCRT Pathway Inhibition
Value PropositionNovel Target: CHMP7, a nuclear pore protein, identified as a key driver in ALS, offers a new therapeutic approach.Disease-Modifying Method: Targets the root cause of nuclear pore complex injury and neural injury, aiming to alter disease progression.Druggable Target: CHMP7 can be inhibited using small molecule, gene, and peptide therapies.Broad...
Published: 3/14/2025
|
Inventor(s):
Jeffrey Rothstein
,
Alyssa Coyne
Keywords(s):
Category(s):
Clinical and Disease Specializations > Neurology > Amyotrophic Lateral Sclerosis
,
Clinical and Disease Specializations > Neurology > Dementia
,
Clinical and Disease Specializations > Neurology > Alzheimer's Disease
,
Clinical and Disease Specializations > Neurology > Huntington's Disease
,
Clinical and Disease Specializations > Neurology > Neurodegeneration
,
Technology Classifications > Therapeutic Modalities > Targets
Treatment of fibrosis-associated pathologies through downstream TGF-尾 pathway inhibition
Value PropositionInhibits downstream signaling pathway of TGF-尾 signaling, reducing pleiotropic and off-target effects.Selectively targets tissue specific calpains, increasing efficacy as compared to current TGF-尾 signaling pathway inhibitory methods.Applicable to several disease models with specific focus on epithelial-to-mesenchymal transition pathologies....
Published: 3/13/2025
|
Inventor(s):
David Kim
,
Harry Dietz
Keywords(s):
Biomarker
,
Cancers
,
Clinical Diagnostics
,
Disease Indication
,
Fibrosis Disorders
,
In Vitro Diagnostics
,
Mechanism-of-action Biomarker
,
Therapeutic Matter
,
Therapeutics
Category(s):
Clinical and Disease Specializations
,
Clinical and Disease Specializations > Fibrosis
,
Clinical and Disease Specializations > Oncology
,
Technology Classifications > Diagnostics > Biomarkers
,
Technology Classifications > Therapeutic Modalities > Targets
,
Technology Classifications > Diagnostics > In Vitro Diagnostics
,
Technology Classifications > Diagnostics
,
Technology Classifications > Therapeutic Modalities
Cell-Permeable Protein Therapeutic for Pain and Itch
Novelty:Identification of a mutant peptide with strong inhibitory effect on nociceptor TRPA1, useful for the prevention and treatment of chronic and acute pain and itch.Value Proposition:Dysregulation of ion channels is associated with various debilitating conditions, including chronic pain and itch. Transient receptor potential ankyrin 1 (TRPA1), an...
Published: 3/13/2025
|
Inventor(s):
Hao-Jui Weng
,
Xinzhong Dong
Keywords(s):
Biologics
,
Biomarker
,
Chronic Pain
,
CNS and Neurological Disorders
,
Disease Indication
,
Mechanism of Action Biomarker
,
Peptide
,
Therapeutic Matter
,
Therapeutic Substance
,
Therapeutics
Category(s):
Clinical and Disease Specializations
,
Clinical and Disease Specializations > Neurology
,
Technology Classifications > Therapeutic Modalities > Biologics
,
Technology Classifications > Therapeutic Modalities > Peptides
,
Technology Classifications > Diagnostics > Biomarkers
,
Technology Classifications > Therapeutic Modalities > Targets
,
Technology Classifications > Diagnostics
,
Clinical and Disease Specializations > Pain
,
Technology Classifications > Therapeutic Modalities
,
Clinical and Disease Specializations > Pain > Chronic Pain
Regeneration of cardiac muscle for the treatment of heart failure
Value Proposition:This technology provides a therapeutic approach for the regrowth of permanently damaged heart muscle.This could improve health outcomes for patients with severe heart failure.Technology DescriptionResearchers at Johns Hopkins have discovered that the manipulation of circadian genes can induce the proliferation and regeneration of cardiomyocytes...
Published: 3/14/2025
|
Inventor(s):
Emmanouil Tampakakis
Keywords(s):
Category(s):
Clinical and Disease Specializations > Cardiovascular
,
Clinical and Disease Specializations > Cardiovascular > Heart Failure
,
Technology Classifications > Therapeutic Modalities
,
Technology Classifications > Therapeutic Modalities > Targets
DNA methylation markers for metastatic prostate cancer
Value Proposition:路 Detection of methylation patterns that are linked to prostate cancer development in an individual.路 Enable development of a personalized treatment plan for individuals with aggressive prostate cancer.路 Simultaneous determination of gene methylation and copy number. Technology DescriptionResearchers at Johns Hopkins...
Published: 3/13/2025
|
Inventor(s):
George Bova
,
William Nelson
,
Martin Aryee
,
William Isaacs
,
Srinivasan Yegnasubramanian
Keywords(s):
Biomarker
,
Cancers
,
Clinical Diagnostics
,
Disease Indication
,
Epigenetic
,
In Vitro Diagnostics
,
Mechanism-of-action Biomarker
,
Methylation
,
Prostate Cancer
,
Therapeutic Matter
,
Therapeutics
Category(s):
Clinical and Disease Specializations
,
Clinical and Disease Specializations > Men's Health
,
Technology Classifications > Diagnostics > Biomarkers
,
Technology Classifications > Diagnostics > In Vitro Diagnostics
,
Technology Classifications > Therapeutic Modalities > Targets
,
Technology Classifications > Diagnostics
,
Clinical and Disease Specializations > Oncology
,
Technology Classifications > Therapeutic Modalities
,
Clinical and Disease Specializations > Oncology > Prostate Cancer
Diagnostic and Treatment Target for Checkpoint Inhibitor Pneumonitis
Unmet Need Checkpoint inhibitor pneumonitis (CIP) can develop as a complication of cancer immunotherapy and is the leading cause of treatment-related death. CIP incidence will continue to rise as immunotherapy treatments become more widespread. However, there are no reliable biomarkers for CIP diagnosis or prognosis. Current approaches for CIP management...
Published: 3/14/2025
|
Inventor(s):
Karthik Suresh
,
Mohammad Ghanbar
,
Franco D'alessio
Keywords(s):
Category(s):
Technology Classifications > Diagnostics > Diagnostic Biomarkers
,
Technology Classifications > Diagnostics > Prognostic Biomarkers
,
Technology Classifications > Therapeutic Modalities > Targets
Hexosamine Analogs for Regenerative Medicine and Diseases Associated with the Musculoskeletal System
Unmet Need:Osteoarthritis (OA) is the most common form of arthritis, affecting an estimated 32.5 million adults in the United States, with an increasing incidence as the population ages (see CDC) . OA is associated with considerable morbidity as a consequence of joint damage, resulting in pain, loss of joint range of motion, and disability. The disease...
Published: 3/13/2025
|
Inventor(s):
Kevin Yarema
,
Jennifer Elisseeff
,
Jeannine Coburn
,
Udayanath Aich
Keywords(s):
Antagonists/Inhibitors
,
Arthritis
,
Biologics
,
Carbohydrates
,
Disease Indication
,
Drug Delivery Mechanism
,
Drug Delivery Vehicle
,
Joint Disorders
,
Novel
,
Osteoarthritis
,
Predicted Novelty
,
Single
,
Small Molecules
,
Targeted Therapy
,
Therapeutic Matter
,
Therapeutic Substance
,
Therapeutics
,
Therapy Type
Category(s):
Clinical and Disease Specializations
,
Technology Classifications > Therapeutic Modalities > Small Molecules
,
Technology Classifications > Therapeutic Modalities > Targets
,
Clinical and Disease Specializations > Rheumatology
,
Technology Classifications > Therapeutic Modalities
,
Clinical and Disease Specializations > Rheumatology > Arthritis
,
Clinical and Disease Specializations > Rheumatology > Osteoarthritis
1
2
3
4
5
6
7
8
9
10
...
JHTV Home
|
Search
|
Login/Subscribe
2017 - 2022 漏 Johns Hopkins Technology Ventures. All Rights Reserved. Powered by
Inteum